Filing Flows › Pacira BioSciences (PCRX) › Q2 2026 › vs Q2 2025
Pacira BioSciences (PCRX) Q2 2026 vs Q2 2025 (year over year)
Pacira BioSciences's revenue rose $11.3M (+6%) from $181M in Q2 2025 to $192M in Q2 2026. The biggest changes: Net product sales +$10.1M (+6%); Royalty revenue +$1.2M (+153%). Operating margin 2.2% against 4.7% (-2.5 pts).
Pacira BioSciences, Q2 2026: revenue $192M (+6% year over year), operating margin 2.2%, net earnings $4.7M, operating cash flow $57.5M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 2.2% | 4.7% | -2.5 pts |
| Net margin | 2.4% | -2.7% | +5.1 pts |
| Free cash flow margin | 29.2% | 5.1% | +24.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| EXPAREL | $148M | $143M | $4.9M | +3% |
| ZILRETTA | $32.6M | $31.3M | $1.3M | +4% |
| iovera° | $6.8M | $5.6M | $1.2M | +22% |
| Bupivacaine liposome injectable suspension | $3.2M | $508K | $2.7M | +533% |
| Net product sales | $190M | $180M | $10.1M | +6% |
| Royalty revenue | $1.9M | $752K | $1.2M | +153% |
| Revenue | $192M | $181M | $11.3M | +6% |
| Operating profit | $4.3M | $8.5M | −$4.2M | -50% |
| Costs & expenses | $188M | $173M | $15.5M | +9% |
| Pre-tax earnings | $2.6M | −$1.9M | $4.5M | — |
| Other expense, net | $1.7M | $10.4M | −$8.7M | -84% |
| Cost of revenue | $44.2M | $40.9M | $3.3M | +8% |
| Research & development | $30.2M | $28.2M | $2.0M | +7% |
| SG&A | $91.8M | $88.6M | $3.2M | +4% |
| Other operating costs | $21.9M | $15.0M | $7.0M | +47% |
| Income tax benefit | $2.1M | −$2.9M | $5.0M | — |
| Net earnings | $4.7M | −$4.8M | $9.5M | — |
| Depreciation & amortization | $21.3M | $27.3M | −$6.0M | -22% |
| Share-based compensation | $15.0M | $15.5M | −$514K | -3% |
| Working capital & other | $16.6M | −$25.9M | $42.5M | — |
| Operating cash flow | $57.5M | $12.0M | $45.4M | +378% |
| Free cash flow (OCF − capex) | $56.1M | $9.3M | $46.8M | +503% |
| Capital expenditures | $1.3M | $2.7M | −$1.4M | -50% |
Questions
How much did Pacira BioSciences's revenue grow year over year in Q2 2026?
Pacira BioSciences's revenue rose $11.3M (+6%) from $181M in Q2 2025 to $192M in Q2 2026.
What drove Pacira BioSciences's revenue change in Q2 2026?
Net product sales +$10.1M (+6%); Royalty revenue +$1.2M (+153%).